AstraZeneca PLC (AZN)
| Market Cap | 267.05B +3.3% |
| Revenue (ttm) | 61.37B +8.6% |
| Net Income | 10.45B +25.9% |
| EPS | 6.72 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 25.61 |
| Forward PE | 16.09 |
| Dividend | $3.23 (1.88%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 4,151,049 |
| Open | 171.54 |
| Previous Close | 171.49 |
| Day's Range | 170.68 - 172.37 |
| 52-Week Range | 153.41 - 212.71 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 206.66 (+20.11%) |
| Earnings Date | Oct 30, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is $206.66, which is an increase of 20.11% from the latest price.
News
AstraZeneca Transcript: Investor update
ESMO results included positive VOLGA bladder-cancer survival data, promising biomarker-selected EGFR combinations, DeLLphi-305 survival gains and positive OS results for Sone-Ve in gastric cancer. Management highlighted ADC growth opportunities and a substantial 2027 readout slate.
AstraZeneca Slides: Investor update
AstraZeneca has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
AstraZeneca's Sone-Ve Cuts Death Risk By 42% In Advanced Gastric Cancer Trial; Stock Up
(RTTNews) - AstraZeneca (AZN) reported positive Phase 3 results showing that sonesitatug vedotin (Sone-Ve) significantly improved overall survival in patients with CLDN18.2-positive advanced gastric, ...
AstraZeneca's Tagrisso Combo Achieves Significant Survival Benefit In Lung Cancer Trial; Stock Up
(RTTNews) - AstraZeneca (AZN) and HUTCHMED reported Phase 3 results showing that Tagrisso (osimertinib) combined with Orpathys (savolitinib) significantly improved progression-free and overall surviva...
Amgen And AstraZeneca's IMDELLTRA Plus IMFINZI Cuts Death Risk By 58% In Small Cell Lung Cancer
(RTTNews) - Amgen (AMGN) and AstraZeneca (AZN) reported Phase 3 results showing that IMDELLTRA combined with IMFINZI significantly improved survival in patients with extensive-stage small cell lung ca...
AstraZeneca Readies New Portfolio of Targeted Cancer Therapies
AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology marke...
Amgen announces Phase 3 results of Imdelltra with AstraZeneca’s Imfinzi
Amgen (AMGN) announced an interim Phase 3 results showing that Imdelltra in combination with AstraZeneca’s (AZN) Imfinzi reduced the risk of death by 58% as a first-line maintenance treatment for…
AstraZeneca announces results from CLARITY-Gastric01 Phase III trial
Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca’s (AZN) sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement ...
AstraZeneca announces results from the SAFFRON Phase III trial of Tagrisso
AstraZeneca (AZN) announces positive results from the SAFFRON Phase III trial showed Tagrisso plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both pr...
AstraZeneca announces results from DeLLphi-305 trial of IMFINZI
Results from the DeLLphi-305 Phase III trial showed IMFINZI plus Amgen’s tarlatamab-dlle demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint o...
AstraZeneca announces results from VOLGA Phase III trial of IMFINZI
Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) IMFINZI in combination with neoadjuvant enfortumab vedotin, EV, demonstrated statistically signi...
AstraZeneca's AZN Reports Breakthrough in Stomach Cancer Treatment, Boosting Dividend Appeal
AstraZeneca's AZN Reports Breakthrough in Stomach Cancer Treatment, Boosting Dividend Appeal
AstraZeneca's stomach cancer drug clears bar for extending overall survival in late-stage study
AstraZeneca's experimental drug sone-ve helped patients with advanced stomach cancer who had received at least two prior treatments to live longer than analysts had expected, according to late-stage t...
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful ...
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab ve...
China-made cancer drug to go on sale in US after Americans travel to buy it
Global pharmaceutical firm AstraZeneca said on Thursday it would start selling a cancer drug after coming under criticism for failing to bring it to the US market faster, prompting some Americans to f...
AstraZeneca PLC Announces US FDA Accelerated Approval of Ultomiris for IgAN on 22 October 2026
AstraZeneca PLC announced that Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) ...
AstraZeneca announces US availability of Zegfrovy
AstraZeneca (AZN) announced the US availability of Zegfrovy for the treatment of adults with locally advanced or metastatic non-small cell lung cancer, NSCLC, whose tumors have epidermal growth factor...
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the US availability of ZEGFROVY® (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung canc...
ZEGFROVY (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
AstraZeneca today announced the US availability of ZEGFROVY (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epiderm...
AstraZeneca's Ultomiris Gets FDA Accelerated Approval As First C5 Inhibitor For IgAN
(RTTNews) - The U.S. FDA on Wednesday approved AstraZeneca (AZN) subsidiary Alexion's Ultomiris to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease pro...
AstraZeneca's Ultomiris Receives Accelerated FDA Approval for Kidney Disease Treatment
AstraZeneca's Ultomiris Receives Accelerated FDA Approval for Kidney Disease Treatment
AstraZeneca's Alexion Unit Gains FDA Nod for Ultomiris in IgAN, Ticker AZN
AstraZeneca's Alexion Unit Gains FDA Nod for Ultomiris in IgAN, Ticker AZN
AstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca says Ultomiris approved to reduce proteinuria
The company states: “Alexion, AstraZeneca (AZN) Rare Disease’s Ultomiris – ravulizumab – has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at...